Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + TNT in locally advanced rectal cancer
NCT06229041Phase 3Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2023
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Started Mar 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06229041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229041.